Lilly Data Point to ‘Maintenance’ Strategies for GLP-1 Weight Loss

Lilly's GLP-1 Drugs Show Promise for Long-Term Weight Maintenance

Eli Lilly has released new data demonstrating the effectiveness of its GLP-1 medicines in helping patients maintain weight loss long-term after initial significant reduction. The research involved patients who had achieved substantial weight loss with either Lilly’s Zepbound or Novo Nordisk’s Wegovy. Participants were then transitioned to either the same high-dose treatment, a lower-dose injection, or Lilly’s new Foundayo pill for a 12-month maintenance period. Both trials showed that these medical interventions significantly outperformed placebo in preventing weight regain. The findings were presented at an obesity conference in Europe and published in The Lancet and Nature Medicine.

• The Surmount-Maintain study focused on patients who initially lost an average of approximately 50 pounds over 60 weeks on the highest tolerated dose of Zepbound. During the subsequent 12-month maintenance phase, those who continued the highest dose lost an additional two pounds, while patients switched to a lower 5-milligram dose gained an average of 12 pounds.
• In the Attain-Maintain study, patients who had initially lost an average of 41 pounds on Wegovy gained only two pounds when transitioned to Lilly’s Foundayo pill for a year. Similarly, patients who had lost an average of 55 pounds on Zepbound gained 11 pounds during the year-long maintenance period on Foundayo.
• These studies address a critical challenge in obesity treatment: the difficulty patients face in adhering to lifelong injectable GLP-1 therapies and the common issue of weight regain upon discontinuation. The results suggest that maintenance strategies, including lower-dose injections or oral medications like Foundayo, can offer viable options for sustained weight management, improving long-term patient outcomes.

Tackling the Challenge of Long-Term Weight Maintenance in Obesity

Current obesity treatment approaches face significant systemic and clinical barriers that limit their effectiveness and accessibility. These challenges span from healthcare delivery and reimbursement issues to fundamental limitations in treatment durability and patient adherence.

• Healthcare system barriers: Determining which healthcare providers should prescribe and manage obesity pharmacotherapy remains unclear, while inconsistent third-party reimbursement across Medicaid, Medicare, and commercial plans severely limits patient access to effective treatments

• Treatment sustainability requirements: GLP-1-based agents and other pharmacotherapies demonstrate substantial weight reduction but require lifelong treatment to sustain benefits, creating long-term cost and adherence challenges

• Drug access and safety concerns: High demand for obesity medications has led to significant drug shortages, compounded by direct-to-consumer marketing, while the proliferation of compounded formulations raises safety and regulatory oversight concerns

• High relapse rates with standard interventions: Lifestyle modifications as first-line treatment carry high risk of relapse, while adherence to recommended drug measures in medium- and long-term treatment remains below 50%

• Limited efficacy of current algorithms: The stepwise treatment approach starting with lifestyle intervention followed by pharmacotherapy, with bariatric surgery reserved as last option, often proves insufficient in terms of efficacy, tolerability, and safety

• Inadequate treatment outcomes: Current treatment efficacy falls far below patients' expectations, with cardiovascular diseases and cancer accounting for the highest mortality rates among obesity-related comorbidities, highlighting the need for more effective early diagnosis and long-term management strategies

Designing for Durability: Surmount-Maintain and Attain-Maintain Trials

Recent obesity trials demonstrate sophisticated methodological approaches across diverse populations and therapeutic interventions. The studies range from pediatric populations to adults with comorbid conditions, employing various randomized controlled trial designs with extended follow-up periods to assess both efficacy and safety outcomes.

Shaping the Future of GLP-1 Maintenance: Oral Foundayo's Role

Several GLP-1 receptor agonists and dual receptor agonists are currently being investigated for similar indications as tirzepatide. These include both established agents undergoing expanded clinical testing and novel compounds with enhanced mechanisms of action.

Lilly's GLP-1s: Reshaping Long-Term Weight Management with Oral Innovation

The latest data from Eli Lilly marks a significant milestone in the evolving landscape of obesity management, underscoring the critical importance of long-term weight loss maintenance. For too long, the challenge in obesity treatment has not just been achieving initial weight reduction, but sustaining it. These findings, demonstrating that GLP-1 medicines like Zepbound and the novel oral Foundayo significantly outperform placebo in preventing weight regain over 12 months, solidify the paradigm shift towards viewing obesity as a chronic condition requiring continuous, effective pharmacotherapy.

A key strategic implication is the potential for Foundayo, an oral GLP-1, to revolutionize patient adherence and access. While injectable GLP-1s have proven highly effective, an oral option could remove a significant barrier for many patients, expanding the addressable market and potentially increasing the duration of treatment. This move also strengthens Lilly's competitive stance, offering a comprehensive solution that can transition patients from initial weight loss (even if achieved with a competitor's injectable) to long-term maintenance with its own portfolio.

However, this promising future is not without its considerations. The well-documented gastrointestinal side effects, such as nausea and vomiting, remain a common reason for treatment discontinuation, particularly at higher doses. Furthermore, the high cost of these advanced therapies and existing limitations in insurance coverage present a substantial barrier to equitable access, threatening to widen health disparities despite the profound public health benefits these drugs offer. While cardiovascular safety has been demonstrated, the long-term effects on bone metabolism are still being evaluated and warrant continued monitoring in larger clinical trials. As the field progresses, addressing these challenges will be crucial to fully realize the transformative potential of GLP-1-based therapies in combating the global obesity epidemic.